Whilst we have investigated the effect of combining gemcitabine with TRAIL as a basis for an improved chemotherapeutic approach, newly emerging immunotherapies targeted against pancreatic cancer that increase the levels of endogenous TRAIL may also benefit from the combined use of gemcitabine59–61. Here, TNFSF10 is linked to familial pancreatic carcinoma.